UnknownNot Applicable

Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients

Denmark40 participantsStarted 2019-06-19

Plain-language summary

Circulating tumor DNA can be used to monitor the treatment effect and identify developing resistance mutations during ALK directed TKI treatment.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Patients with ALK translocated metastatic NSCLC, treated with alectinib as 1st line therapy in routine clinical practice
✓. Written (personally dated and signed) informed consent

PFS on alectinib

Timeframe: 46 month

mechanism of resistance

Timeframe: 15.2 month

NCT IDNCT04708639

SponsorAarhus University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-06-30